CMG's guaranteed health and biotechnology fund plans to invest 80% of the fund in treasury bonds and the remaining 20% in 43 actively managed drug, biotech, specialty pharmaceutical and medical technology stocks. Of these, 60% will be pharmaceutical stocks and 14% biotechnology stocks. As long as investors don't withdraw their money before the fund matures in March 2004 they will get back, at a minimum, their principal, minus...